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Abstract
Background: TCF7L2 belongs to a subfamily of TCF7-like HMG box-containing transcription
factors, and maps to human chromosome 10q25.3. A recent study identified genetic association of
type 2 diabetes (T2D) with this gene, correlated with diminished insulin secretion. This study aimed
to investigate the possibility of genetic association between TCF7L2 and type 1 diabetes (T1D).
Methods: The SNP most significantly associated with T2D, rs7903146, was genotyped in 886 T1D
nuclear family trios with ethnic backgrounds of mixed European descent.
Results: This study found no T1D association with, and no age-of-onset effect from rs7903146.
Conclusion: This study suggests that a T2D mechanism mediated by TCF7L2 does not participate
in the etiology of T1D.
Background
Recently, a new type 2 diabetes (T2D) susceptibility gene,
transcription factor 7-like 2 (TCF7L2), was identified[1].
Subsequently, many studies confirmed this novel associa-
tion[2-12], which accounts for the highest T2D risk con-
firmed to date. TCF7L2 belongs to a subfamily of TCF7-
like HMG box-containing transcription factors, and maps
to human chromosome 10q25.3[13]. It is a component of
the Wnt signaling pathway, and participates in the tissue-
specific regulation of expression of proglucagon gene,
which has been shown critical in blood glucose homeos-
tasis[14]. Because of the effects on blood glucose homeos-
tasis, the TCF7L2 gene variation may also be important in
type 1 diabetes (T1D). To investigate the possibility of this
association, we genotyped the marker most significantly




Genomic DNA (gDNA) was obtained after informed con-
sent from T1D-affected subjects and their two parents
(886 trios or 2,658 individuals after removing families
with Mendelian discrepancies at multiple independent
SNPs). The Research Ethics Board of the Montreal Chil-
dren's Hospital and other participating centers approved
the study. Ethnic backgrounds were of mixed European
descent, with the largest single group being of Quebec
French-Canadian origin (40% of the total collection).
SNP Genotyping
The SNP rs7903146 was genotyped by the Sequenom
MassARRAY system (Sequenom, San Diego CA, USA).
Primers for PCR and MassEXTEND reaction to detect
sequence differences at the single nucleotide level were
designed using Assay Design software. PCR primers: for-
ward, 5'-ACGTTGGATGGGTGCCTCATACGGCAATTA-3';
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reverse, 5'-ACGTTGGATGTCTCTGCCTCAAAACCTAGC-
3'. The extension primer, 5'-AGAGCTAAGCACTTTTTA-
GATA-3'. We amplified 2.5 ng of gDNA in a 5 µl volume.
After dephosphorylation of unincorporated dNTPs, allele-
specific primer extension reaction was performed to gen-
erate different sizes of extension products corresponding
to each allele by the Sequenom iPLEX™ technology. Sam-
ples were conditioned to remove extraneous salts and gen-
otypes were called based on the presence of different sizes
of extension products by the Matrix Assisted Laser Desorp-
tion Ionization Time Of Flight (MALDI-TOF) mass spec-
trometry technology[15]. The call rate of this SNP is
99.6% and the Mendelian error rate is 0.2%.
Statistics
Hardy-Weinberg equilibrium (HWE) of the genotype dis-
tribution in parents of the T1D families was tested by the
following equation.
ν = 1; a, b and c are the frequencies of, respectively, the C/
C, C/T or T/T genotypes.
Transmission disequilibrium test (TDT) was performed
by the Haploview software[16]. The age effect among dif-
ferent genotypes was tested by both ANOVA and the non-
parametric Kruskal-Wallis Test.
Results and discussion
The minor allele T of rs7903146 has a frequency of 0.303
in the parents of the T1D families, which is similar to the
frequencies of control groups in the T2D studies. The gen-
otype distribution in the parents was in HWE (χ2 = 0.0, ν
= 1, p = 0.972), compatible with the absence of stratifica-
tion, admixture or technical artifacts. Our study found no
T1D association from rs7903146. The transmission ratio
T/C = 369/342 (χ2 = 1.0, p = 0.311).
For a SNP with the minor allele frequency of 0.303, the
statistical power at α = 0.05 level of our family-based asso-
ciation study on 886 affected nuclear family trios is shown
in Figure 1. Our study has a statistic power of > 80% at α
= 0.05 level to detect a genetic association with an effect
size as low as OR = 1.23. Besides the HLA region[17], pre-
viously confirmed T1D associations have been replicable
in our dataset, including the weak effect from the SNP
rs231775 on the CTLA4 gene(Table 1). Considering the
important role of TCF7L2 in glucose homeostasis, one
possibility that needs to be excluded is that the TCF7L2
gene variation might accelerate the onset of clinical symp-
toms of T1D. We compared the age-of-onset of different
genotypes of the TCF7L2 rs7903146 (Table 2). We found
no age-of-onset effect from the TCF7L2 variation. There-
fore, our result suggests that the genetic variation of
TCF7L2 has no obvious effect on T1D.
TCF7L2 encodes a transcription factor, also known as T-
cell transcription factor 4 (TCF4). TCF4 acts through bind-
ing with β-catenin as a complex, and consequently acti-
vates the expression of TCF4-regulated genes[18,19]. How
the TCF7L2 variation changes the gene function is unclear
yet. TCF4 is a 596aa peptide (NP_110383.1), which con-
tains two conserved domains, the CTNNB1_binding
domain and the SOX-TCF_HMG-box domain. The
CTNNB1_binding domain locates from the 1st to the
236th amino acid, which binds to β-catenin and forms the
active complex. The SOX-TCF_HMG-box domain locates
from the 330th to the 397th amino acid, which binds to
specific DNA motif and regulates gene transcription.
Sequencing of all the exons of TCF7L2 in 184 individuals
(93 T2D cases and 91 controls) has found no nonsynon-
ymous SNP (nsSNP)[1]. The possibility of protein-
sequence polymorphism can be excluded as the basis for
the T2D susceptibility. Therefore, the T2D susceptibility
should be from the change of gene expression level result-
ing from regulatory genetic variation. The TCF7L2 gene
spans ~216 kb and ~750 SNPs have been identified in this
region. As shown by the international HapMap project
data, TCF7L2 spans several linkage disequilibrium (LD)
blocks in Europeans[20]. The T2D-associated SNPs are
from the largest LD block spanning ~65 kb, which starts
from the middle of intron 3, and ends at the first seventh
of intron 4[1,21]. The genetic regulation on TCF7L2
expression can be from the change of mRNA processing or
alternative splicing from a variation in the gene intronic
region. There is no published information on any such
effects; unpublished data from our lab (Marchand et al.,














Table 1: Transmission disequilibrium tests of the SNPs in the INS, PTPN22, and CTLA4 gene in the T1D trio set used in this study
gene dbSNP ID minor allele (frequency) Transmission ratio* χ2 (p value) OR (95% CI)
INS rs689 T (0.207) 186:387 70.5 (4.58 × 10-17) 0.48 (0.40, 0.57)
PTPN22 rs2476601 A (0.126) 251:123 43.8 (3.62 × 10-11) 2.04 (1.64, 2.53)
CTLA4 rs231775 G (0.387) 443:382 4.5 (0.034) 1.16 (1.01, 1.33)
CTLA4 rs5742909 T (0.090) 137:178 5.3 (0.021) 0.77 (0.62, 0.96)
* Minor allele transmitted : untransmitted.BMC Medical Genetics 2007, 8:51 http://www.biomedcentral.com/1471-2350/8/51
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mRNA levels or relative abundance of splicing isoforms in
the few tissues examined to date.
T2D results from a progressive insulin secretory defect on
a background of insulin resistance[22]. However, the role
of TCF7L2 in the T2D mechanism is unclear. Present stud-
ies show contradictory results on the effect of the TCF7L2
gene variation on insulin secretion and insulin sensitivity.
Florez JC, et al, showed that the T2D-predisposing haplo-
type correlates with diminished insulin secretion but has
no effect on insulin response[3]. On the other hand,
Elbein SC, et al, showed that the TCF7L2 gene variation is
correlated with reduced glucose tolerance and insulin sen-
sitivity, but not insulin secretion[23]. In either case, it
would have been reasonable to hypothesize that the T2D-
The statistical power of this study to detect a genetic association with the minor allele frequency of 0.303 at α = 0.05 level Figure 1
The statistical power of this study to detect a genetic association with the minor allele frequency of 0.303 at α = 0.05 level. X-
axis: the OR value; Y-axis: the statistical power.
Table 2: The age-of-onset of T1D of three rs7903146 genotypes
genotype number average age-of-onset (  ± s) Median
C/C 355 8.1 ± 4.3 8.3
C/T 323 8.8 ± 5.6 8.1
T/T 74 8.3 ± 5.6 7.6
F value (p) F = 1.540 (p = 0.215)
Kruskal Wallis test χ2 = 1.427 (p = 0.490)
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risk genotypes at TCF7L2 may accelerate the clinical onset
of T1D symptoms; none was seen in our study.
Conclusion
Our study suggests the TCF7L2 gene variation does not
participate in the etiology of T1D. During the manuscript
preparation of this study, another report of no association
between T1D and TCF7L2 was published, which is con-
cordant with our conclusion[24]. The combined results of
both studies clearly show that the genetic susceptibility
from the TCF7L2 gene variation is a unique mechanism of
T2D, and is not shared by T1D.
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